"As a translational scientist, I enjoy being an integral part of the essential feedback loop that extends from the lab bench to the clinic and back!"
Prior to coming to Genentech in 2004, I worked in target discovery at SUGEN, evaluating novel kinases for their potential as cancer targets. Here at Genentech, my primary role has shifted to that of an in vivo pharmacologist, shepherding early stage research projects through the drug development process, all the way into the clinic. The career transition from basic to applied research has been particularly rewarding in that I enjoy working with passionate and talented cross-functional team members to deliver drugs that will directly benefit patients’ lives.
Mol Cancer Ther. 2013 Oct;12(10):1968-80.
My group provides preclinical pharmacology support for numerous pipeline projects, (small molecule inhibitors, biologics, antibody-drug conjugates, etc.). In this capacity, we perform in vivo studies in pathway-relevant animal models. By understanding drug behavior in a model organism, we can provide biological rationale for the optimal dose and schedule, anticipate potential therapeutic risks, confirm diagnostic hypotheses and pioneer biomarker assays that will guide critical clinical development decisions.